Treatment of Ovarian Cancer in Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT)
Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is a rare and aggressive malignancy that requires a structured, protocol-driven approach. Management decisions depend on disease stage, surgical findings, and response to initial therapy.
Clinical Scenario
This protocol applies to patients with confirmed small cell carcinoma of the ovary, hypercalcemic type (SCCOHT). The diagnosis defines a distinct high-risk subpopulation of ovarian cancer requiring a treatment pathway specific to this histology.
Treatment Approach (Partial Overview)
For initial responders, the approach involves surgical staging and, where appropriate, consolidation with high-intensity systemic therapy. For patients with progressive or recurrent disease, select immunotherapy-based regimens or combination chemotherapy may be considered — the complete treatment algorithm, sequencing, and eligibility criteria are detailed in the full protocol.
Full regimen, sequencing, and clinical criteria not shown here.
References
- Small cell carcinoma of the ovary (hypercalcemic type) (SCCOHT)
- Consider high-dose chemotherapy with autologous stem cell transplantation as consolidation
- Pembrolizumab
- Ipilimumab + Nivolumab
- Paclitaxel + Bevacizumab
View source ↗